1172 related articles for article (PubMed ID: 28494868)
1. Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression.
Garcia-Diaz A; Shin DS; Moreno BH; Saco J; Escuin-Ordinas H; Rodriguez GA; Zaretsky JM; Sun L; Hugo W; Wang X; Parisi G; Saus CP; Torrejon DY; Graeber TG; Comin-Anduix B; Hu-Lieskovan S; Damoiseaux R; Lo RS; Ribas A
Cell Rep; 2017 May; 19(6):1189-1201. PubMed ID: 28494868
[TBL] [Abstract][Full Text] [Related]
2. IFNγ-induced PD-L1 expression in ovarian cancer cells is regulated by JAK1, STAT1 and IRF1 signaling.
Padmanabhan S; Gaire B; Zou Y; Uddin MM; Vancurova I
Cell Signal; 2022 Sep; 97():110400. PubMed ID: 35820543
[TBL] [Abstract][Full Text] [Related]
3. BCL6-Mediated Silencing of PD-1 Ligands in Germinal Center B Cells Maintains Follicular T Cell Population.
Peng C; Hu Q; Yang F; Zhang H; Li F; Huang C
J Immunol; 2019 Feb; 202(3):704-713. PubMed ID: 30567732
[TBL] [Abstract][Full Text] [Related]
4. Met inhibition revokes IFNγ-induction of PD-1 ligands in MET-amplified tumours.
Martin V; Chiriaco C; Modica C; Acquadro A; Cortese M; Galimi F; Perera T; Gammaitoni L; Aglietta M; Comoglio PM; Vigna E; Sangiolo D
Br J Cancer; 2019 Mar; 120(5):527-536. PubMed ID: 30723303
[TBL] [Abstract][Full Text] [Related]
5. Closed system RT-qPCR as a potential companion diagnostic test for immunotherapy outcome in metastatic melanoma.
Gupta S; McCann L; Chan YGY; Lai EW; Wei W; Wong PF; Smithy JW; Weidler J; Rhees B; Bates M; Kluger HM; Rimm DL
J Immunother Cancer; 2019 Sep; 7(1):254. PubMed ID: 31533832
[TBL] [Abstract][Full Text] [Related]
6. Triptolide reduces PD-L1 through the EGFR and IFN-γ/IRF1 dual signaling pathways.
Xie Y; Ding J; Gao J; Zhang J; Cen S; Zhou J
Int Immunopharmacol; 2023 May; 118():109993. PubMed ID: 36931170
[TBL] [Abstract][Full Text] [Related]
7. JAK2 and PD-L1 Amplification Enhance the Dynamic Expression of PD-L1 in Triple-negative Breast Cancer.
Chen M; Pockaj B; Andreozzi M; Barrett MT; Krishna S; Eaton S; Niu R; Anderson KS
Clin Breast Cancer; 2018 Oct; 18(5):e1205-e1215. PubMed ID: 29933930
[TBL] [Abstract][Full Text] [Related]
8. A secondary role for hypoxia and HIF1 in the regulation of (IFNγ-induced) PD-L1 expression in melanoma.
van Duijn A; Willemsen KJ; van Uden NOP; Hoyng L; Erades S; Koster J; Luiten RM; Bakker WJ
Cancer Immunol Immunother; 2022 Mar; 71(3):529-540. PubMed ID: 34268602
[TBL] [Abstract][Full Text] [Related]
9. PD-L1 and PD-L2 expression correlated genes in non-small-cell lung cancer.
Larsen TV; Hussmann D; Nielsen AL
Cancer Commun (Lond); 2019 Jun; 39(1):30. PubMed ID: 31159869
[TBL] [Abstract][Full Text] [Related]
10. Association of PD-1/PD-L axis expression with cytolytic activity, mutational load, and prognosis in melanoma and other solid tumors.
Danilova L; Wang H; Sunshine J; Kaunitz GJ; Cottrell TR; Xu H; Esandrio J; Anders RA; Cope L; Pardoll DM; Drake CG; Taube JM
Proc Natl Acad Sci U S A; 2016 Nov; 113(48):E7769-E7777. PubMed ID: 27837027
[TBL] [Abstract][Full Text] [Related]
11. Comprehensive assessment of PD-L1 and PD-L2 dysregulation in gastrointestinal cancers.
Zhao Q; Guo J; Zhao Y; Shen J; Kaboli PJ; Xiang S; Du F; Wu X; Li M; Wan L; Li X; Wen Q; Li J; Zou C; Xiao Z
Epigenomics; 2020 Dec; 12(24):2155-2171. PubMed ID: 33337915
[No Abstract] [Full Text] [Related]
12. JAK2, PD-L1, and PD-L2 (9p24.1) amplification in metastatic mucosal and cutaneous melanomas with durable response to immunotherapy.
Gupta S; Vanderbilt CM; Cotzia P; Arias Stella JA; Chang JC; Chen Y; Tang LH; DeLair DF; Yao J; Ladanyi M; Ross DS
Hum Pathol; 2019 Jun; 88():87-91. PubMed ID: 30236595
[TBL] [Abstract][Full Text] [Related]
13. SOX10 Regulates Melanoma Immunogenicity through an IRF4-IRF1 Axis.
Yokoyama S; Takahashi A; Kikuchi R; Nishibu S; Lo JA; Hejna M; Moon WM; Kato S; Zhou Y; Hodi FS; Song JS; Sakurai H; Fisher DE; Hayakawa Y
Cancer Res; 2021 Dec; 81(24):6131-6141. PubMed ID: 34728538
[TBL] [Abstract][Full Text] [Related]
14. Myeloid maturation potentiates STAT3-mediated atypical IFN-γ signaling and upregulation of PD-1 ligands in AML and MDS.
Yoyen-Ermis D; Tunali G; Tavukcuoglu E; Horzum U; Ozkazanc D; Sutlu T; Buyukasik Y; Esendagli G
Sci Rep; 2019 Aug; 9(1):11697. PubMed ID: 31406210
[TBL] [Abstract][Full Text] [Related]
15. IFNγ induces PD-L1 overexpression by JAK2/STAT1/IRF-1 signaling in EBV-positive gastric carcinoma.
Moon JW; Kong SK; Kim BS; Kim HJ; Lim H; Noh K; Kim Y; Choi JW; Lee JH; Kim YS
Sci Rep; 2017 Dec; 7(1):17810. PubMed ID: 29259270
[TBL] [Abstract][Full Text] [Related]
16. IFN-gamma-induced PD-L1 expression in melanoma depends on p53 expression.
Thiem A; Hesbacher S; Kneitz H; di Primio T; Heppt MV; Hermanns HM; Goebeler M; Meierjohann S; Houben R; Schrama D
J Exp Clin Cancer Res; 2019 Sep; 38(1):397. PubMed ID: 31506076
[TBL] [Abstract][Full Text] [Related]
17. Interplay between interferon regulatory factor 1 and BRD4 in the regulation of PD-L1 in pancreatic stellate cells.
Ebine K; Kumar K; Pham TN; Shields MA; Collier KA; Shang M; DeCant BT; Urrutia R; Hwang RF; Grimaldo S; Principe DR; Grippo PJ; Bentrem DJ; Munshi HG
Sci Rep; 2018 Sep; 8(1):13225. PubMed ID: 30185888
[TBL] [Abstract][Full Text] [Related]
18. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
19. Tumor Interferon Signaling Is Regulated by a lncRNA INCR1 Transcribed from the PD-L1 Locus.
Mineo M; Lyons SM; Zdioruk M; von Spreckelsen N; Ferrer-Luna R; Ito H; Alayo QA; Kharel P; Giantini Larsen A; Fan WY; Auduong S; Grauwet K; Passaro C; Khalsa JK; Shah K; Reardon DA; Ligon KL; Beroukhim R; Nakashima H; Ivanov P; Anderson PJ; Lawler SE; Chiocca EA
Mol Cell; 2020 Jun; 78(6):1207-1223.e8. PubMed ID: 32504554
[TBL] [Abstract][Full Text] [Related]
20. Inhibition of PI3Kδ Differentially Regulates Poly I:C- and Human Metapneumovirus-Induced PD-L1 and PD-L2 Expression in Human Bronchial Epithelial Cells.
Ogawa T; Kan-O K; Shiota A; Fujita A; Ishii Y; Fukuyama S; Matsumoto K
Front Immunol; 2021; 12():767666. PubMed ID: 34899719
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
